TL;DR
These findings highlight nanobodies as versatile platforms capable of overcoming key limitations of conventional therapies and facilitating clinical translation in precision oncology.
By overcoming key limitations of conventional antibodies, engineered nanobodies open new avenues for precise, multi-dimensional interventions in solid tumors and highlight the value of engineered Nbs as a highly programmable and transformative platform.
This perspective summarizes the current landscape of biomedical nanotechnologies and outlines how their continued evolution positions nanomedicine as an enabling science driving the next generation of therapeutics.
Novel NCs like microemulsions, vesicular (liposomes), and nanoparticular NCs are created and explored, which have unique improved penetration and retention in the tumour tissue.
This review summarizes the discovery and structural characteristics of nanobodies, the construction strategies for NDCs, their applications in tumor therapy, and the synergistic potential of nanobodies with other treatment modalities to provide insights for future research and development of NDCs in oncology.
This review systematically examines the hierarchical organization of BDDS across nanoscale, microscale, and macroscale levels and emphasizes their distinct biological advantages, engineering features, and translational potential.
This review article focuses on CAR-T cell bioengineering, antitumor mechanism of action, challenges and limitations, as well as the latest innovative nanotechnological solutions for complementing CAR-T cell immunotherapy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
